Alpha-Lipoic Acid for the Prevention of Diabetic Macular Edema by Haritoglou, Christos et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 EURETINA – Original Paper 
 Ophthalmologica 2011;226:127–137 
 DOI: 10.1159/000329470 
 Alpha-Lipoic Acid for the Prevention of 
Diabetic Macular Edema
 Christos Haritoglou  a     Joachim Gerss  b     Hans P. Hammes  c     Anselm Kampik  a     
Michael W. Ulbig  a     for the RETIPON Study Group  1  
 a 
  Department of Ophthalmology, Ludwig Maximilian University,  Munich ,  b   Institute of Biostatistics and 
Clinical Research, University of Münster,  Münster , and  c   5th Medical Department, University Hospital
Mannheim,  Mannheim , Germany 
 
mellitus (IDDM) with a median duration of diabetes of 9.3 
versus 9.0 years in the placebo group. Visual acuity remained 
unchanged during the entire trial. Concerning the primary 
endpoint, the study provided a negative result, i.e. 26/235 
patients in the treatment group and 30/232 patients in the 
placebo group developed CSME. Confirmatory intention-to-
treat analysis of the primary endpoint revealed no statisti-
cally significant difference between groups (log-rank test, 
p = 0.7108, HR = 0.9057 with CI = 0.5355–1.5317). Median 
follow-up was identical (2.00 years).  Conclusions: A daily 
dosage of 600 mg ALA does not prevent the occurrence of 
CSME in IDDM patients.  Copyright © 2011 S. Karger AG, Basel
 Introduction
 Diabetic retinopathy including macular edema is the 
most frequent cause of blindness in Western industrial-
ized nations  [1–3] . Prevention of visual loss depends on 
timely detection of diabetic retinopathy and instant-laser 
treatment. As a timely and close glycemic control with 
near-normal HbA1c levels and blood pressure below 
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 Abstract
 Introduction: To evaluate the effect of   -lipoic acid (ALA) 
 on the occurrence of diabetic macular edema.  Methods: 
Randomized, double-blind, placebo-controlled, multicenter, 
multinational study. Patients were randomized to the treat-
ment group with 600 mg ALA per day or the placebo group. 
Every 6 months stereo fundus photographs, HbA1c levels, 
and an ophthalmological examination were documented. 
The primary endpoint was the occurrence of clinically sig-
nificant macular edema (CSME) within a follow-up period of 
2 years.  Results: We randomized 235 patients with type II 
diabetes mellitus into the treatment group (mean age 58.0 
years) and 232 into the placebo group (mean age 57.9 years). 
Mean HbA1c level was 8.1, with no significant differences be-
tween the treatment (mean 8.2, SD  8 1.35) and placebo 
groups (mean 8.1, SD  8 1.29). HbA1c values remained con-
stant over time. In the treatment and placebo groups, 84 and 
86 patients (35.7 and 37.1%) had insulin-dependent diabetes 
 Received: April 29, 2011 
 Accepted after revision: May 4, 2011 
 Published online: July 29, 2011 
Ophthalmologica
 Christos Haritoglou, MD
 Department of Ophthalmology, Ludwig Maximilian University
 Mathildenstrasse 8
 DE–80336 Munich (Germany)
 Tel. +49 895 160 3084, E-Mail christos.haritoglou   @   med.uni-muenchen.de 
 © 2011 S. Karger AG, Basel
 0030–3755/11/2263–0127$38.00/0 
 Accessible online at:
 www.karger.com/oph 
 1  See Appendix 1 for participating centers and investigators.  C.H. and J.G. contributed equally to this work. 
 Haritoglou  /Gerss  /Hammes  /Kampik  /
Ulbig  
Ophthalmologica 2011;226:127–137 128
130/80 mm Hg cannot always be achieved, medical ther-
apy to prevent the occurrence and progression of sight-
threatening complications remains a challenge. 
 Retinal damage induced by diabetic macular edema is 
due to vascular leakage and nonperfusion  [4] . Sustained 
hyperglycemia affects several vasoactive factors, notably 
vascular endothelial growth factor, protein kinase C and 
angiotensin II, all of which are interrelated and may in-
fluence the development of structural and functional 
changes in diabetic retinopathy  [4–9] . The upregulation 
of vascular endothelial growth factor is associated with a 
breakdown of the blood-retinal barrier and increased 
vascular permeability resulting in retinal edema  [9, 10] . 
High glucose levels in endothelial cells are associated 
with a mitochondrial overproduction of reactive oxygen 
species, which inactivate glyceraldehyde-3-phosphate de-
hydrogenase  [11] . This process plays a role in the patho-
genesis of endothelial damage  [12] . Therefore, antioxi-
dants appear to be a therapeutic approach.   -Lipoic acid 
(ALA) differs in several aspects from other antioxidants 
 [13–15] as it distributes to mitochondria, has a very low 
redox potential, recycles other cellular antioxidant redox 
pairs (such as ascorbate) and is regenerated by hypergly-
cemia and nonessential fatty acid-induced nicotinamide 
adenine dinucleotide phosphate (via pyruvate dehydro-
genase), linking the antioxidant activity to the degree of 
increased metabolic flux  [16] . 
 The potential of ALA in preventing microvascular 
damage has been demonstrated in animals  [17] . ALA has 
been used for years in the long-term treatment of chron-
ic sensorial disorders in diabetic polyneuropathy at a dos-
age of 600 mg/day. We raised the hypothesis that a ben-
eficial effect may also be seen in diabetic retinopathy and 
in the prevention of clinically significant macular edema 
(CSME)  [18–24] . 
 Methods
 Study Design
 The RETIPON Study is a phase III, randomized, multicenter, 
multinational, double-blind, placebo-controlled, comparative 
trial to evaluate a potential effect of ALA in prolonging the time 
interval between the diagnosis of mild to moderate diabetic reti-
nopathy at enrolment and the development of CSME in high-risk 
insulin-dependent diabetes mellitus (IDDM) patients. 
 The study was approved by the local ethics committee.
 Inclusion and Exclusion Criteria ( table 1 )
 We included outpatients, male or female, with diagnosed 
adult-onset IDDM, aged 45–68 years, showing mild to moderate 
nonproliferative diabetic retinopathy (NPDR) according to the 
classification of the ETDRS protocol  [25] in at least one eye and 
presenting with microalbuminuria  1 30 mg/l as diagnosed with a 
urine dipstick microalbumin test (Micro-Bumintest  , Bayer  , 
Leverkusen, Germany). These patients are known to bear a high 
risk for microvascular complications such as CSME. Patients were 
insulin dependent or non-insulin dependent. Written informed 
consent had to be given. 
 Treatment Modalities and Randomization
 The 600-mg dosage of ALA was established for treatment of 
peripheral polyneuropathy. The chemical name of the investiga-
tional drug is 1,2-dithiolane-3-valeric acid. The trial medication 
 Table 1.  Exclusion criteria
 Ophthalmic exclusion criteria 
 –  Severe nonproliferative or proliferative diabetic retinopathy  
 –  Macular edema 
 –  Eye diseases interfering with the examinations of the fundus 
such as preretinal hemorrhage, cataract, vitreous hemorrhage 
 –  Amblyopia 
 –  Best corrected visual acuity ≤0.5 
 –  Glaucoma 
 –  Patients with cataract surgery within a period of 3 months 
 –  Other relevant retinal diseases 
 –  Unauthorized interventional therapy of diabetic retinopathy 
(e.g. laser, kryocoagulation, vitrectomy) 
 General exclusion criteria 
 –  Chronic administration of ALA or for more than 5 successive 
days during the last 12 months 
 –  Known intolerance/hypersensitivity to ALA 
 –  Type I diabetes mellitus 
 –  Poor metabolic control with HbA 1c >10.5%/dl 
 –  Late sequelae of diabetes with organic manifestation (e.g.
 dialysis in cases of renal insufficiency, history of kidney
 transplantation, creatinine >1.6 mg/dl) 
 –  Poorly controlled arterial hypertension (systolic blood
 pressure >160 mm Hg and/or diastolic blood pressure
 >95 mm Hg) 
 –  Severe disturbances in lipid metabolism (triglycerides >500 
mg/dl or total cholesterol >320 mg/dl) 
 –  Unauthorized concomitant medications, defined as any
 medicine with a potential interaction with ALA or with the
 effect of ALA, were excluded as concomitant medications. 
These included aldose reductase inhibitors, substances
 promoting blood flow, anticoagulants apart from
 acetylsalicylic acid ≤500 mg/day and short-term treatment of 
diseases with the normal dose of acetylsalicylic acid,
 chronically and systemically administered corticosteroids,
 hormonal contraceptives 
 –  Malignancies or life-threatening diseases 
 –  Drug or alcohol abuse 
 –  Blood donation or blood loss greater than 500 ml within the 
last 3 months 
 –  Pregnancy or breast-feeding 
 –  Participation in a clinical trial within the last 30 days 
 
 Alpha-Lipoic Acid for the Prevention of 
Diabetic Macular Edema 
Ophthalmologica 2011;226:127–137 129
was prepared in compliance with Good Manufacturing Practice 
(GMP), packed and supplied by Bausch & Lomb, Berlin, Ger-
many).
 The trial medication had been granted marketing authoriza-
tion and was newly packed in blister packs and relabeled as 600-
mg tablets. The placebo and the drug tablets were similarly packed 
and labeled, and had an identical appearance and taste.
 The number of tablets dispensed at the visits was recorded 
and subjects were instructed to return any unused medication at 
the next visit. All returned medications were counted to deter-
mine the actual number of tablets taken. Noncompliance was 
defined as an intake of less than 80% of the medication between 
visits.
 Eligible patients accomplished a 4-week compliance test phase 
starting with visit 1. In case of at least 80% compliance, they were 
randomized at visit 2 (day 0) to receive either ALA 600-mg tablets 
once daily or placebo for a 24-month period. After inclusion, pa-
tients were followed at 6-month intervals.
 A block design was used for randomization. Random numbers 
were allocated in ascending order corresponding to the order in 
which subjects were included after the examination on visit 2. 
Each patient was allocated to either active treatment or placebo 
using a stratified randomization within the investigation center 
as well as the following strata: 1 = HbA1c  ! 9%, IDDM; 2 = HbA1c 
 ! 9%, non-IDDM (NIDDM); 3 = HbA1c  6 9%, IDDM, and 4 = 
HbA1c  6 9%, NIDDM.
 Date and time of randomization (i.e. the time point at which 
the current random number was allocated) were recorded for each 
subject. The balance of randomization was approved.
 The randomization code for the trial investigational medici-
nal product was provided to the investigator in separate sealed 
envelopes (emergency envelope) labeled with trial and random-
ization code numbers. The breaking of the treatment code was 
strictly forbidden except in the event of a medical emergency. The 
sponsor had to be immediately notified and the reason for break-
ing the code documented in the subject’s medical records and on 
the case report form. The investigator assessed the relationship of 
the adverse event to the trial investigational medicinal product 
before the treatment code was broken. 
 Medical Review and Physical Examination
 Blood samples for laboratory tests obtained at visit 1, and 3–6 
included RBC, WBC, platelet count, hemoglobin, hematocrit, 
GOT, GPT,   -GT, creatinine, urea, uric acid, HbA1c, fasting 
blood glucose, total cholesterol, triglycerides. Morning urine was 
checked by a dipstick test for glucose, total protein, and bilirubin 
at visit 1 on-site. Laboratory tests were performed in a single cen-
tral laboratory for all centers (MDS Pharma Services, Hamburg, 
Germany). Clinically relevant findings were documented in the 
case report form as adverse events and treated accordingly. All 
clinically relevant abnormal laboratory results were to be followed 
up until they returned to normal (i.e. to baseline), stabilized or 
could be explained otherwise.
 At the initial visit, the patient’s body weight, height, blood 
pressure and concomitant medication were recorded. In addition, 
a complete medical examination was performed. Systolic and di-
astolic blood pressure and pulse rate were measured at visit 1 and 
visits 3–6 after a 10-min rest in the supine position and recorded 
in the case report form. All blood pressure measurements were 
made on both arms using a sphygmomanometer with an appro-
priate cuff size for the individual subject and the mean value was 
calculated. 
 Ophthalmic Examination and Method of Macular Edema 
Detection
 At each visit, i.e. every 6 months, patients underwent bilateral 
eye examination including best corrected visual acuity using the 
Early Treatment Diabetic Retinopathy Study (ETDRS) charts, slit 
lamp examination, intraocular pressure, and stereoscopic biomi-
croscopy. Seven-field stereo fundus photographs (in color 30°) ac-
cording to the criteria of the ETDRS protocol  [25] were taken. The 
quality of the photographs was assessed immediately upon receipt 
by the senior author (M.W.U.). In cases of insufficient quality, the 
respective center was asked to submit a new set of photographs. 
Fluorescein angiography at the beginning and end of the study 
was optional and evaluated according to the ETDRS protocol  [26] . 
Adverse events whether or not considered to be caused by the 
study medication had to be reported. 
 Macular edema was diagnosed on stereoscopic fundus photo-
graphs according to the ETDRS protocol  [26] . The fundus photo-
graphs were always evaluated by two masked examiners at the 
RETIPON Reading Center in Munich, Germany, under the guid-
ance of the senior author (M.W.U.). Both graders had to concur 
 on the final assessment and potential differences in the grading 
were discussed by the graders. Graders were all certified to 
 ETDRS standards. The same applied for all participating photog-
raphers in the study centers. Optical coherence tomography 
(OCT) scans were neither adequate nor possible. Most participat-
ing centers had no OCT device, and OCT scans are more useful 
to measure changes in preexisting macular thickening.
 Primary and Secondary Endpoints
 Detection of CSME in at least one eye was defined as the pri-
mary endpoint. Both eyes were graded at each visit. Following 
detection of CSME in the central reading center, its occurrence 
was immediately reported and the patient was appropriately treat-
ed by laser and excluded from further follow-up.
 Secondary objectives were the development of neovasculariza-
tion elsewhere or at the disk, changes in severity of diabetic reti-
nopathy according to the ETDRS severity scale  [25] , the course of 
best corrected visual acuity, and contrast sensitivity as well as cat-
aract formation measured by the Lens Opacity Classification Sys-
tem II.
 Statistical Analysis
 The statistical evaluation was based on a group sequential de-
sign with one interim and a final analysis. Using the O’Brien-
Fleming approach and the Lan-De Mets   -spending function 
methodology in the primary analysis, the single significance lev-
els for an overall level of   = 0.05 are   1  = 0.0054 for the interim 
analysis and   2  = 0.0492 for the final analysis. This report pre sents 
the results of the final analysis. 
 As in the O’Brien-Fleming approach, the final analysis keeps 
close to the overall significance level and has approximately the 
same power as a fixed-sample design, a fixed-sample approach 
was applied for sample size and power calculation. The effect size 
estimation was based on expert ratings from experienced oph-
thalmologists. It was assumed that we had a 62% event-free 
 survival in the placebo group after 2 years and a 75% event-free 
survival in the treatment group. Given these assumptions and 
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 accounting for a 20% rate of nonevaluable patients, a required 
sample size of n = 260 recruited patients per group was calculated, 
providing 80% power of significantly detecting treatment differ-
ences in the primary analysis. Finally, slightly fewer patients have 
actually been recruited. Recalculation of the power, however, 
showed that it still was acceptable, amounting to 75%.
 The primary endpoint was evaluated by a two-sided log-rank 
test, comparing the two treatment groups in an intention-to-treat 
approach (ITT). This particular hypothesis test provides confir-
matory statistical evidence and constitutes the primary study re-
sult. Further supplementary analyses of the primary endpoint 
were performed, including Kaplan-Meier plots, a corresponding 
per-protocol analysis, and confidence interval (CI) estimation of 
the hazards ratio (HR) between the two treatment groups. Pro-
portional hazard assumptions were verified using the Grambsch-
Thernau residual-based test. Secondary endpoints were evaluat-
ed, comparing means and proportions of the parameters given 
above between treatment groups with Student’s t test and the   2  
test, respectively. Bonferroni adjustment was applied to prevent 
type I error enhancement due to multiplicity.
 Beyond analyses of primary and secondary endpoints, explor-
atory analyses were performed. The homogeneity of the treatment 
groups was checked with regard to demographic and relevant pre-
treatment data. Further exploratory analyses comprised evalua-
tion of safety data, subgroup analyses, and multivariate analyses 
of the time to CSME development.
 Statistical analyses were performed using SAS software (Ver-
sion 9.1.3 for Windows, SAS Institute Inc., Cary, N.C., USA). In 
 Table 2.  Summary of baseline characteristics
 ALA  Placebo  Total  p value 
 Randomized, n 235 232 467 
 Demographic characteristics 
 Sex 
 Male, n 101 (43.0%) 94 (40.5%) 195 (41.8%)  0.5897  Female, n 134 (57.0%) 138 (59.5%) 272 (58.2%) 
 Age, years 
 Mean  8 SD  58.0 8 6.11  57.9 8 6.30  57.9 8 6.20  0.8556  Range 44–68 45–69 44–69 
 Baseline characteristics 
 Degree of retinopathy 
 Microaneurysms only, n 17 (7.2%) 14 (6.0%) 31 (6.6%) 
 0.4342 
 Mild NPDR, n  188 (80.0%)  196 (84.5%)  384 (82.2%) 
 Moderate NPDR, n 28 (11.9%) 22 (9.5%) 50 (10.7%) 
 Moderately severe NPDR, n 1 (0.4%) 0 1 (0.2%) 
 Severe NPDR, n 1 (0.4%) 0 1 (0.2%) 
 Type of treatment for DM 
 IDDM, n 84 (35.7%) 86 (37.1%)  170 (36.4%)  0.7662  NIDDM, n  151 (64.3%)  146 (62.9%)  297 (63.6%) 
 Stratum 1, HbA1c <9%, IDDM, n 53 (22.6%) 56 (24.1%)  109 (23.3%) 
 0.9821  Stratum 2, HbA1c <9%, NIDDM, n  110 (46.8%)  107 (46.1%)  217 (46.5%)  Stratum 3, HbA1c ≥9%, IDDM, n  31 (13.2%) 30 (12.9%) 61 (13.1%) 
 Stratum 4, HbA1c ≥9%, NIDDM, n 41 (17.4%) 39 (16.8%) 80 (17.1%) 
 Median duration of DM, years 9.3 9.0 9.1  0.7348 
 Mean HbA1c (SD, range), % 8.2 (1.35, 3.8–10.5) 8.1 (1.29, 5.3–10.5) 8.1 (1.32, 3.8–10.5)  0.4087 
 Study discontinuation 
 Total (at least one of the below reasons), n  39 (16.6%)  29 (12.5%)  68 (14.6%)  0.2096 
 HbA1c >10.5% at two consecutive regular 
 follow-up visits, n 
 
6 (2.6%) 
 
6 (2.6%) 
 
 12 (2.6%) 
 Inability to comply with the study medication, n 1 (0.4%) 0 1 (0.2%) 
 Inability to comply with the visit schedule 
 and/or lost of follow-up, n 
 
7 (3.0%) 
 
8 (3.4%) 
 
 15 (3.2%) 
 Malignant or other life-threatening diseases, n 2 (0.9%) 2 (0.9%) 4 (0.9%) 
 Necessity of not permitted concomitant medication, n 0 1 (0.4%) 1 (0.2%) 
 Unacceptable adverse events, n 4 (1.7%) 2 (0.9%) 6 (1.3%) 
 Withdrawal of consent, n  19 (8.1%)  10 (4.3%)  29 (6.2%) 
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general, descriptive analyses were performed, describing quanti-
tative variables by number of values, number of missing values, 
mean, standard deviation (SD), minimum, median and maxi-
mum (or median and interquartile range if appropriate). Qualita-
tive variables were described by absolute and relative frequencies 
of incidence or absolute and relative frequencies of variable cate-
gories. Moreover, inductive statistical analyses were performed, 
applying appropriate significance tests and calculating CIs. Miss-
ing values were not replaced.
 Withdrawal
 All subjects were free to withdraw from this trial at any time, 
for any reason, specified or unspecified and without impact on 
their future treatment. Reasons for withdrawal are summarized 
in  table 1 . 
 Results
 Baseline Characteristics ( table 2 ) and Main Efficacy 
Results
 All outcome assessments were performed by masked 
examiners. Of all 467 patients, 235 were randomized into 
the treatment group and 232 into the placebo group. In 
the treatment group, 101 patients (43.0%) were male and 
134 female (57.0%), versus 94 (40.5%) and 138 (59.5%) in 
the placebo group. Mean age was 58.0 years in the treat-
ment group and 57.9 years in the placebo group. Best 
 corrected visual acuity over all patients measured with 
ETDRS letters (both eyes) was 108.9 in the treatment 
group and 106.9 in the placebo group at visit 1 (p = 
 0.0991) and remained unchanged until the final visit 
(107.9 vs. 104.6, p = 0.1464).
 Mean HbA1c level was 8.1 ( 8 1.32 SD), with no signif-
icant differences seen following randomization at study 
entry when comparing the treatment group and place - 
bo group. HbA1c values remained constant over time in 
all randomization strata. In the treatment and placebo 
groups, 84 (35.7%) versus 86 (37.1%) patients had IDDM 
and median duration of diabetes was 9.3 versus 9.0 years, 
respectively. For rates and reasons for study discontinua-
tion, see  table 2 .
 At baseline, the degree of retinopathy did not signifi-
cantly differ between treatment groups (p = 0.4342). 
Subsequently, the degree of retinopathy deteriorated in 
the placebo group with borderline significance (p = 
0.0708) whereas it remained constant over time in the 
treatment group. On visit 3, significant differences in the 
degree of retinopathy emerged between the two groups 
(p = 0.0311). On visits 4, 5 and 6, however, the degree 
of retinopathy did not show any differences between 
groups anymore. A more detailed description of the par-
ticipants, randomization and reasons of withdrawal is 
shown in  figure 1 . 
 Comorbidity and Need for Medication Emerging 
during Therapy ( table 3 )
 Apart from IDDM, the most common concomitant 
conditions were hypertension (62.5%), coronary artery 
disease (8.6%), ischemic cardiomyopathy (7.5%), and dys-
lipidemia (7.1%). Other conditions were documented in 
less than 6% of the ITT population. In total, 463 patients 
treated with an ITT approach (99.1%) were taking a con-
comitant medication during the trial. Most prevalent 
concomitant medications, except those used for the treat-
ment of diabetes, were enalapril maleate (27.4%), indap-
amide (19.3%), and acetylsalicylic acid (12.2%).
 Primary Endpoint
 Concerning the primary endpoint, i.e. the cumula-
tive CSME probability, the study provided a negative re-
sult: within the total observational period, 26/235 pa-
tients of the treatment group and 30/232 patients of the 
placebo group developed CSME. Confirmatory ITT 
analysis of the primary endpoint revealed no statisti-
cally significant difference between the two groups (log-
rank test, p = 0.7108, HR = 0.9057 with CI = 0.5355–
1.5317). Median follow-up was identical in the two 
groups (2.00 years). 
 Univariate Predictors of CSME Development ( table 4 )
 Looking at all randomized patients (n = 467), 411 pa-
tients did not develop CSME during the follow-up, while 
CSME was observed in 56 patients. Gender, HbA1c, body 
weight, body mass index, arterial hypertension, duration 
of diabetes, age and degree of retinopathy were no sig-
nificant predictors of CSME development. Diabetes 
 treatment (IDDM vs. NIDDM) turned out to be the only 
baseline covariate with a significant predictive capacity 
for CSME development (HR = 2.025, CI = 1.199–3.421, 
 p = 0.0083). 
 Multivariate Analysis of CSME Development
 The time to CSME development was modeled in a 
multivariate approach using the baseline covariates gen-
der, diabetes treatment, HbA1c, body weight, body mass 
index, arterial hypertension, duration of diabetes, age, 
degree of retinopathy and treatment with ALA versus 
placebo. Except for diabetes treatment, none of the co-
variates proved to significantly influence CSME develop-
ment. In the full model including all above covariates, the 
HR of IDDM versus NIDDM was 2.691 (CI = 1.469–4.929, 
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232 patients randomized to
placebo
235 patients randomized to
ALA treatment
467 patients enrolled
(ITT population = safety population)
196 patients included
in the PP analysis
6 patients
1 patient
7 patients
2 patients
0 patients
4 patients
19 patients Withdrawal of consent
Inacceptable adverse event
Inability to comply with study medication
HbA1c >10.5%/dl at two
consecutive regular follow-up visits
Inability to comply with visit
schedule and/or lost to follow-up
Malignant or other life-threatening
disease
Necessity of unauthorized
concomitant medication
203 patients included
in the PP analysis
6 patients
0 patients
8 patients
2 patients
1 patient
2 patients
10 patients
 Fig. 1. Consort flow chart of the RETIPON 
Study. PP = Per protocol. 
 Table 3. L ist of cardiovascular risk factors, concomitant diseases and medications
 ALA  (n = 235)  Placebo (n = 232) 
 Risk factors for cardiovascular disease 
 Baseline characteristics: blood pressure category high, n   208 (88.5%)  196 (84.5%) 
 Medical history: hypertension, n  146 (62.1%)  146 (62.9%) 
 Baseline characteristics: current smoker, n  29 (12.3%) 33 (14.2%) 
 Disorder of lipid metabolism, n   168 (71.5%)  172 (74.1%) 
 Baseline characteristics: weight  6 80 kg, n   115 (48.9%)  119 (51.3%) 
 Most frequent findings of medical history 
 Metabolism and nutrition disorders, n   235 (100.0%)  232 (100.0%) 
 Nervous system disorders, n  16 (6.8%) 19 (8.2%) 
 Cardiac disorders, n  59 (25.1%) 65 (28.0%) 
 Vascular disorders, n   150 (63.8%)  149 (64.2%) 
 Eye disorders, n  40 (17.0%) 40 (17.2%) 
 Most prevalent concomitant medications 
 Agents acting on the renin-angiotensin system, n   131 (55.7%)  136 (58.6%) 
 Antithrombotic agents, n  30 (12.8%) 35 (15.1%) 
  -Blocking agents, n  43 (18.3%) 60 (25.9%) 
 Calcium channel blockers, n  56 (23.8%) 48 (20.7%) 
 Cardiac therapy, n  54 (23.0%) 59 (25.4%) 
 Diuretics, n  53 (22.6%) 65 (28.0%) 
 Drugs used in diabetes, n   234 (99.6%)  223 (96.1%) 
 Serum lipid-reducing agents, n  32 (13.6%) 36 (15.5%) 
 C oncomitant medication such as acetylsalicylic acid (up to 500 mg/day), antihypertensives and diuretics were permitted as long as 
such treatments had been applied for at least 3 months, were to be continued for the duration of the clinical trial, and the patient met 
the inclusion criteria. 
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p = 0.0013). IDDM increases the risk of developing CSME 
by a factor of 2.691 compared to NIDDM. The only rele-
vant covariates, diabetes treatment and HbA1c (i.e. the 
covariates determining the randomization strata), and 
(randomized) treatment with ALA versus placebo were 
included in a reduced model. The reduced model allows 
for estimation of the adjusted treatment effect that results 
if the possible confounders, diabetes treatment and 
HbA1c, are kept constant. The adjusted HR of ALA treat-
ment versus placebo amounts to 0.911 (CI = 0.539–1.541, 
p = 0.7276), indicating that active treatment does not sig-
nificantly influence the time to CSME development. In 
further model-based analyses, it was investigated wheth-
er ALA treatment possibly shows interaction effects with 
baseline covariates. Interaction tests did not yield any 
positive results, indicating that the treatment effect was 
independent of baseline covariates, i.e. there was a null 
effect.
 Table 4.  Univariate predictors of CSME development
 Potential predictors  Univariate HR  CI  p value 
 Males versus females  1.288  0.761–2.178  0.3461 
 HbA1c ≥9% versus <9%  1.045  0.591–1.848  0.8802 
 Body weight ≥80 kg versus <80 kg  0.865  0.511–1.462  0.5870 
 Body mass index ≥30 versus <30  0.673  0.377–1.203  0.1816 
 Systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg versus
 systolic BP <140 mm Hg and diastolic BP <90 mm Hg 
 
 0.965 
 
 0.564–1.651 
 
 0.8974 
 Annual increase in the duration of diabetes  0.995  0.957–1.035  0.8076 
 Annual increase in age  1.008  0.965–1.052  0.7199 
 Mild diabetic retinopathy versus microaneurysms only   1.182  0.367–3.811  0.7791 
 At least moderate diabetic retinopathy versus 
 microaneurysms only 
 
 2.172 
 
 0.598–7.892  
 
 0.2389 
 IDDM versus NIDDM  2.025  1.199–3.421  0.0083 
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log-rank p = 0.7108
HR (ALA versus placebo) = 0.91 (95% CI = 0.54–1.53)
ALA
Placebo
Numbers at risk
ALA 225
228
222 201 189 97 0
Placebo
Time after inclusion (years)
 Fig. 2. Confirmatory ITT analyses of pri-
mary endpoint. The cumulative probabil-
ity of developing CSME did not signifi-
cantly differ between the treatment and 
the placebo group (log-rank test, p = 
0.7108, HR = 0.9057 with CI = 0.5355–
1.5317). During the study period, 26/235 
patients in the treatment group and 30/232 
patients in the placebo group developed 
CSME. 
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 Subgroup Analyses ( table 5 )
 Exploratory post-hoc analyses were performed in or-
der to investigate whether ALA treatment might have a 
positive impact on the time to CSME development in 
certain subgroups of patients. In none of the subgroups 
did a significant treatment effect emerge. Moreover, no 
systematic pattern became apparent that might possibly 
have indicated a slight trend towards a beneficial treat-
ment effect, e.g. in ‘high-risk’ subgroups of patients.
 Safety Results
 During the trial, 109 (46%) subjects of the ALA group 
and 112 (48%) subjects of the placebo group reported 
TEAEs. Most frequently occurring events were infec-
tions, metabolism and nutrition disorders, vascular dis-
orders, cardiac disorders and nervous system disorders. 
 Comparing the ALA and the placebo group, TESAEs 
were reported by 9% versus 10% of subjects. TEAEs in 10 
versus 4 subjects were considered to be related to the trial 
treatment; 11 subjects in both groups reported events of 
severe intensity, 4 versus 2 terminated the trial prema-
turely due to TEAEs, death (SAEs) occurred in 2 versus 3 
subjects.
 Conclusions
 Diabetes increases oxidative stress, which is postulat-
ed to play an important role in the development of its mi-
crovascular complications  [27] , such as retinopathy and 
macular edema, a potentially sight-threatening condi-
tion. In rats, ALA has been shown to prevent microvas-
cular damage by normalizing pathways downstream of 
mitochondrial overproduction of reactive oxygen species 
and to preserve pericyte coverage of retinal capillaries, 
which may provide additional endothelial protection  [16] . 
Others described beneficial effects on diabetic retinopa-
thy via inhibition of accumulation of oxidatively modi-
fied DNA and nitrotyrosine  [17] . Therefore, we assumed 
that supplementation with antioxidants such as ALA as 
an adjunct therapy may help to reduce the risk of visual 
loss in diabetic humans with NPDR.
 For the present trial, we deliberately selected a high-
risk population of IDDM patients with NPDR and micro-
albuminuria as especially the latter factor is known as a 
strong predictor of the development of microvascular 
and macrovascular complications  [28] and assumed that 
this population may be suitable to detect potential protec-
 Table 5.  Subgroup analysis of time to CSME development
 P atients  HR  95% CI  p 
 value ALA placebo 
 Stratum 1 53 56  1.3522  0.5842–3.1301  0.4811 
 Stratum 2  110  107  0.9570  0.3679–2.4893  0.9282 
 Stratum 3 31 30  0.7389  0.1653–3.3031  0.6921 
 Stratum 4 41 39  0.4227  0.1092–1.6355  0.2122 
 Male sex  101 94  1.3272  0.6096–2.8898  0.4758 
 Female sex  134  138  0.6395  0.3040–1.3451  0.2386 
 Body weight <80 kg  120  113  0.5748  0.2735–1.2082  0.1440 
 Body weight ≥80 kg  115  119  1.5204  0.6976–3.3139  0.2919 
 BMI <30   151  144  0.9419  0.5062–1.7527  0.8501 
 BMI ≥30  84 88  0.8286  0.3084–2.2268  0.7094 
 Systolic BP <140 mm Hg and 
 diastolic BP <90 mm Hg 
 
 100 84 
 
 0.7750 
 
 0.3342–1.7973 
 
 0.5526 
 Systolic BP ≥140 mm Hg or 
 diastolic BP ≥90 mm Hg 
 
 135 
 
 148 
 
 0.9988 
 
 0.5091–1.9594 
 
 0.9972 
 Baseline degree of retinopathy 
 Microaneurysms only 17 14 
 
 1.7096 
 
 0.1550–18.8565 
 
 0.6615 
 Mild NPDR  188  196  0.7167  0.3888–1.3212  0.2858 
 Moderate, moderately severe or severe NPDR 30 22  1.5270  0.3816–6.1105  0.5496 
 Sub groups are determined by randomization strata (i.e., diabetes treatment and HbA1c), gender, body 
weight, body mass index, and hypertension. The univariate HR of ALA treatment versus placebo is estimated 
in each subgroup, supplemented by the 95% CI and a Wald   2  significance test. 
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tive effects of our study medication. The Wisconsin data 
on the risk of developing macular edema  [29] were based 
on HbA1c levels beyond 10%. In our study, we aimed at 
an average HbA1c level of 8%. However, we observed that 
ALA at the dose of 600 mg/day provided no significant 
protective effect on the occurrence of CSME. Differences 
in the level of retinopathy as seen during the first follow-
up visits can be neglected, as all patients included pre-
sented with very mild NPDR and low retinopathy levels. 
Mild changes in the retinopathy level as seen in the pla-
cebo group have no clinical relevance either. No differ-
ences between the placebo and the treatment group con-
cerning retinopathy levels were noted later on during the 
trial.
 A number of clinical trials, such as the ALADIN (I, II, 
and III), SYDNEY (I and II), and ORPIL, using ALA have 
been undertaken in diabetic patients to treat symptom-
atic diabetic peripheral neuropathy  [30–36] using oral 
ALA supplements from 600 up to 1,800 mg/day. ALA was 
administered both intravenously at doses of 600–1,200 
mg/day for up to 3 weeks, sometimes combined with pro-
longed administration of additional oral medications 
 [30–37] . Some of these reports described less symptoms 
of peripheral neuropathy  [30, 34–36] , while others noted 
no clinically meaningful effect compared with placebo 
 [32] . The fact that some positive results have been report-
ed in diabetic neuropathy following ALA treatment but 
not in the prevention of diabetic macular edema may 
point to different pathomechanisms, and suggests that 
neuroglial damage is not an early event in diabetic macu-
lar edema formation while the breakdown of the blood-
retinal barrier is the predominant causative mechanism. 
An improvement in insulin sensitivity in IDDM patients 
following the oral administration of ALA was also de-
scribed  [33] .
 The observations described in the present clinical tri-
al on human diabetic patients stand in contrast to previ-
ously reported findings in rats  [16, 17] . However, in both 
animal studies, much higher ALA concentrations of 60 
mg/kg  [16] and 400 mg/kg body weight were adminis-
tered over a period of 30 versus 44 weeks. One may con-
clude that the dosage of 600 mg/day in an adult (7.5 mg/
kg body weight in an 80-kg adult) as in our study may not 
have been high enough to exert a permanent effect on the 
human retina. No upper limit for ALA intake in humans 
has been established yet. In contrast, safety levels have 
been described for animals with pronounced species-de-
pendent differences, showing that rats appear to be far 
more tolerant than many other species, such as dogs 
(LD 50  for dogs 400–500 mg/kg  [36] vs.  1 2,000 mg/kg for 
rats  [37] ). Some groups reported that an oral dose of 600 
mg once daily appeared to provide the optimum risk-to-
benefit ratio  [38] . Our daily dosage of 600 mg/day was 
within the range of ALA dosages reported in the litera-
ture and could be considered safe. 
 One may suggest that 2 years’ ALA administration 
was too short. In published clinical trials, the duration of 
oral ALA supplementation at a dose of 600 mg/day ranged 
from 4 weeks  [33] to 2 years (combined with an initial in-
travenous injection of 600 mg for 3 days in the study by 
Reljanovic et al.  [31] . In similar ophthalmological trials, 
such as the CALDIRET study  [39] , a follow-up of 5 years 
was eventually found to be too long because the final re-
sult was predictable already after 2 years. 
 One may criticize that imaging techniques, such as 
OCT, were not part of the protocol of this trial. This is due 
to the fact that OCT was not available at all study centers, 
especially in Eastern Europe. However, according to the 
ETDRS protocol, the gold standard for the first detection 
of macular edema is stereoscopic photography, as done in 
this trial. 
 In summary, antioxidants such as ALA have become 
popular in different medical fields. While a positive effect 
in the treatment of diabetic patients using the dosage of 
600 mg/day appears to be beneficial for neuropathy, no 
protective effect regarding the development of macular 
edema, another microvascular complication in diabe-
tes, was seen in high-risk IDDM patients using the same 
dosage. Therefore, regular ophthalmological surveillance 
and interdisciplinary cooperation remain mandatory.
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 Appendix 1
 
 Centers and principal investigators participating in the clinical trial (28 centers in 5 countries)
 Country  Center and principal investigator 
 Germany  Eye Disease Clinic, Greifswald (Principal Investigator: Prof. Stefan Clemens). 
 University Eye Clinic, Leipzig (Principal Investigator: Prof. Sebastian Wolf). 
 Poland  Medical Academy I Ophthalmology Department, Lublin (Principal Investigator: Prof. Zbigniew Zagórski). 
 Medical Academy, Ophthalmology Department & Clinic, I Physician’s Faculty, Warsaw
 (Principal Investigator: Prof. Tadeusz Kęcik). 
 Ophthalmology Office, Katowice (Principal Investigator: Dr. Henryk Kozioł). 
 Provincial Hospital Podkarpacki Named Jana Pawła II, Ophthalmology Department, Krosno 
 (Principal Investigator: Dr. Antoni Bąk). 
 Ophthalmology Department & Clinic by Silesian Medical Academy in Katowice, Bytom 
 (Principal Investigator: Prof. Stefan Pojda). 
 Ophthalmology Office Krzysztof Dzięgielewski s.c., Łódź (Principal Investigator: Prof. Jerzy Nawrocki). 
 Ukraine  Medical Academy of Postgraduate Education, Department of Ophthalmology, Eye Microsurgery Center, Kyiv 
 (Principal Investigator: Prof. Nikolaj M. Sergienko). 
 Filatov Institute of Eye Diseases and Tissue Therapy of Academy of Medical Sciences of Ukraine, Odessa 
 (Principal Investigator: Prof. Natalia Pasechnikova). 
 Romania  Opticontact and Occulus Center, Bucharest (Principal Investigator: Dr. Ozana Manuela Cernica). 
 Ophthalmologic private practice, Brasov (Principal Investigator: Dr. Stefan Sisak). 
 Clinical County Hospital No. 1 – Ophthalmology, Timisoara 
 (Principal Investigator: Dr. Valerica Augustin Ivanescu). 
 Central Military Hospital, Bucharest (Principal Investigator: Prof. Benone Cârstocea). 
 Diabetics and Nutrition Diseases Institute, Bucharest (Principal Investigator: Dr. Simona Barsan). 
 University Clinic Hospital Sfantul Spiridon, Clinic of Ophthalmology, Iasi 
 (Principal Investigator: Prof. Dr. Dorin Chiselita). 
 Cluj County Hospital, Cluj (Principal Investigator: Prof. Dr. Mihai Calugaru). 
 Russia  Endocrinological Scientific Center, Moscow (Principal Investigator: Prof. Marina Shestakova). 
 Chair of Endocrinology and Diabetology of the Russian State University, City Clinical Hospital No. 1, Moscow 
 (Principal Investigator: Prof. Irina Demidova). 
 City Multi Field Hospital No. 2, Endocrinology Department, St. Petersburg 
 (Principal Investigator: Dr. Alsou Zalevskaya). 
 Chair of Endocrinology of Novosibirsk Medical Academy, District Clinical Hospital, Novosibirsk 
 (Principal Investigator: Prof. Irina Bondar). 
 Chair of Endocrinology and Diabetology of the Russian Medical Academy for Advanced Medical Studies, 
 Railway Clinical Hospital, Moscow (Principal Investigator: Prof. Alexandre Ametov). 
 Chair of Ophthalmology of the Russian State Medical University, City Clinical Hospital No. 15, Moscow
 (Principal Investigator: Prof. Eugeniy Egorov). 
 Chair of Endocrinology and Diabetology of EPGE Setchenov MMA, City Clinical Hospital No. 67, Moscow
 (Principal Investigator: Prof. Mihail Balabolkin). 
 Study centers of the RETIPON Study distributed into Western and Eastern European centers. 
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